Three of these programs are based on dasigluca gon, a stable glucagon analog: a new drug application will be submitted in poglycemia in diabetes; ongoing Phase 3 for treatment of the rare pediatric condition, congenital hyperinsu linism; and Phase 3 planned for use in dual-hormone fully automated pump therapy for management of type 1 diabetes.